• The University of British Columbia (UBC) will conduct a double-blind study of Lexaria’s TurboCBD™ oral ingestion product
• TurboCBD™ masks foul tastes, protects pharmaceutical ingredients during stomach passage and increases intestinal absorption by 5-10x
• The UBC study will include 24 volunteers and test their cognitive and cardiovascular function after single doses and after seven days of administration

Traditionally, cannabidiol (CBD) is ingested via inhalation, which can harm the lungs, and many edible products contain unwanted sugars or sweeteners. Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) has revolutionized oral intake with its TurboCBD™ product. Engineered to increase absorption through the intestinal tract, without active compounds destroyed by stomach acid or broken down by the liver, the product also masks the flavor of compounds with undesirable tastes. In August 2017, the University of British Columbia (UBC) announced (http://dtn.fm/f8UPH) that it will conduct the first clinical study of the high-absorption product while evaluating its effects on cognitive function and cardiovascular health of human volunteers.

Currently, Lexaria is the only company to have been awarded a patent for delivery of ingestible non-psychoactive cannabinoids. It holds patents in the U.S. and Australia, and more are pending in over 40 other countries. The upcoming UBC study will be double-blind and placebo controlled. Researchers will measure the effects after a single dose and after seven days of daily doses. The 24 volunteers will consist of young and old individuals, whose glucose, blood pressure, vascular function, cognition, and physical performance will be measured. Blood samples, exercise tests, heart rate, respiration, and neuropsychological tests, among other measurements, will be conducted as well. These tests will provide a complete set of pharmacokinetic and pharmacodynamic performance data of Lexaria’s TurboCBD™.

Regarding the expected outcome of the study, professor Philip Ainslie, PhD, stated in the recent report, “…To quantify the pharmacokinetics of TurboCBD™ will allow us to make informed recommendations of optimum dosing in order to improve vascular health and performance throughout healthy aging. Once we understand these processes better, the applications to various clinical populations can then be explored…”

Details of the test results are expected to be released once the study is completed and the data are interpreted.

According to Lexaria, its “plant-to-bloodstream” product amplifies intestinal absorption by 5-10x. It uses fatty acids, which combine with the active pharmaceutical ingredient to block them from bitter taste receptors on the tongue. Active ingredients are protected by lipids as they pass through the stomach. In the small intestine, long chain fatty acids are absorbed directly into the lymphatic system, while medium chain fatty acids are absorbed via the liver.

An August 2015 in vitro absorption study, conducted in a third party lab, found a 499 percent increase in CBD bioabsorption in the intestines. A human focus study in March 2016 revealed the onset of THC effects in 15 to 20 minutes, while test subjects praised the taste of the product. The company also entered into a collaborative research agreement with Canada’s National Research Council, which was signed in February 2017.

For more information, visit the company’s website at www.LexariaEnergy.com

Let us hear your thoughts: Lexaria Bioscience Corp. Message Board

• The holding company, through its subsidiaries, operates in California and permits players to buy, manage their Lotto tickets online, and receive exclusive special lottery news
• Eyeing expansion in the U.S., LTTGF has hired legal contractor to begin due diligence process for launch into other states
• James Morel, president and CEO, said online site has been redesigned, marketing campaigns readied, as company now operates in the $6.3 billion lottery market in California

LottoGopher Holdings, Inc. (OTCQB: LTTGF) (CSE: LOTO) (FRA: 2LG) has named William Shatner as its spokesperson, the company announced (http://dtn.fm/h7cPd). One of the world’s best-known actors, in addition to being a director, author, and singer, Shatner is a pop icon figure and Canadian-born personality. Shatner has starred in Star Trek, Boston Legal, and T.J. Hooker, and he has appeared in numerous other TV shows, movies, and plays.

LTTGF, based in Vancouver, British Columbia, operates in California as a lottery messenger service that permits users to not only buy state lottery tickets, but also manage them, using debit or credit cards online. LTTGF users can play alone with a single ticket or join online public or private groups to pool winnings from lotteries, including Powerball, Mega Millions and Super Lotto Plus. LTTGF also enables Californians to keep track of their winnings while participating in multiple lottery contests with multiple tickets. It gives members exclusive lottery news, jackpot alerts and lucky number pickers.

“I am very happy to be joining the LottoGopher team,” Shatner stated in a news release. “Much like Netflix disrupted the movie rental business and Uber hailing a cab, LottoGopher is disrupting the lottery industry for Americans.” He noted that LTTGF enables consumers to buy lottery tickets online in a cost-effective manner and that he looks forward to helping their customers dream big.

In 1997, Shatner teamed with discount travel site Priceline (NASDAQ: PCLN). The Nasdaq-listed stock had an IPO price of $16 per share before skyrocketing to $1,868. Today, the company has a market cap of $99 billion.

In a recent news release, James Morel, president and CEO of LTTGF, said, “We are beyond thrilled that William Shatner has agreed to collaborate with us to accelerate awareness of the brand as our spokesperson.” A humorous digital marketing campaign is also being readied.

He added that Shatner would open up a “huge audience base” for LTTGF’s online messenger service. “He is one of the most recognizable celebrities in the world.”

For a direct link to the William Shatner video, go to http://dtn.fm/fs0LD

For more information, visit the company’s website at www.LottoGopher.com

Let us hear your thoughts: LottoGopher Holdings Inc. Message Board

• Offering superior online training for small/medium-sized businesses, previously accessible to only larger companies
• Recent acquisitions and joint ventures have expanded ProBility’s offerings to include more products and cover more industries than ever before
• Company now includes Brown Technical Media Corp., Brown Technical Publications Inc., Brown Book Shop, Inc., National Electrical Wholesale Providers, W Marketing, One Exam Prep, LLC, ProBility Safety Academy, ProBility Immersive Technologies, Cranbury International and its partnership with GlobalSim Inc.

ProBility Media Corp (OTCQB: PBYA) has been driven to serve as many customers in diverse fields as possible, and a solid acquisition and growth strategy has helped it become an emerging leader in the eLearning and training segment. It is developing a full-service training and career advancement brand that is benefiting small- and medium-sized companies that can now have access to the same resources as their larger counterparts. Its product offerings include high-tech training that incorporates intensive interactive media such as virtual reality and 3D modeling. Thanks to ProBility, clients can find these products and more without having to resort to gathering them from multiple sources, saving time, effort and money.

Having recently acquired National Electrical Wholesale Providers and W Marketing, Inc., ProBility now serves the electrical industry. A variety of educational courses and exam preparation products are accessible through the company’s website. Any electrical contractor can obtain the training they need and learn how to properly install, maintain, and repair power, lighting, and communication systems. There is also a digital media library of intellectual property animations, plus subscription services that energy/industrial employers can take advantage of.

The EdTech company has expanded its scope as much as its industry reach. With the purchase of Cranbury International, it can now offer the same breadth of service to the Caribbean, Central America, and South America. It also now offers heating ventilation and air conditioning training via Brown Technical, plus training materials on ASTM codes and standards, and plumbing and pipefitting training courses, handbooks, and other materials.

Its 1 Exam Prep division enables ProBility to offer access to exam preparation at the state, county, or OSHA level. Many of these are business- and industry-specific, allowing those preparing for such examinations to perfect their test-taking skills ahead of time. There are also numerous resources for employers that want to manage their training on-premises.

An expanding set of training, compliance and career advancement materials are open to businesses in over 60 trades. Electrical, HVAC, plumbing, crane operations and boilermakers are just a few of them. The ProBility Safety Academy, a joint venture with Range Guard and Investigations, extends courses and exam-prep materials to law enforcement, private security and criminal justice segments in a more accessible way than ever before.

ProBility has rapidly become a source of comprehensive online training and exam preparation in multiple industries. Quick and direct access via the Web means that employers don’t have to look far to provide their workforce with industry-leading training that will boost the career potential of their workers and provide these organizations with well-prepared and informed individuals.

For more information, visit the company’s website at www.ProbilityMedia.com

Let us hear your thoughts: ProBility Media Corp. Message Board

• Partnership between Algae Dynamics and Dr. Steven Laviolette focuses on medical benefits of cannabis and hemp oils for various mental health disorders
• Canada is moving to legalize cannabis throughout the country in 2018, which could radically change research playing field
• Canadian cannabis oil extraction market projected to reach $1.5 billion by 2020

Algae Dynamics Corp. (OTCQB: ADYNF), a Canadian company focused on the development of proprietary research and products derived from cannabis and hemp oils, has begun a collaborative relationship with one neuroscientist who is looking deep within the brain for answers to some of the world’s most pressing mental health problems.

This research agreement with Dr. Laviolette, a neuroscientist at the University of Western Ontario, Canada, is no small thing. The level of human misery and the resulting global economic burden caused by neurological and mental health disorders is hard to fathom. The World Health Organization reports that failure to adequately address and provide effective treatment for depression and other anxiety disorders could cost the world $1 trillion each year, according to research published in The Lancet (http://dtn.fm/8bROv).

“I started working with Algae Dynamics in the spring of this year and it’s going really well, we’re already making quite a bit of progress,” Dr. Laviolette said. “They’re very open-minded and they appreciate the science. They understand the best products come from the best quality science, so I’m very excited to be working with them.”

Algae Dynamics approached Dr. Laviolette, because he was already examining how cannabinoids can treat disorders such as addiction, schizophrenia, depression and post-traumatic stress disorder.

“We’ve been looking at how we can more effectively utilize different chemicals that are found in marijuana to serve as more effective treatments for some of these devastating illnesses,” Dr. Laviolette says. “Algae Dynamics was taking a holistic approach to this research by not only looking at the specific cannabinoids in marijuana, but they also have a background in the extraction of various nutritional dietary products such as Omega-3 fatty acids. That was very exciting for me.”

Emerging research shows that Omega-3 fatty acids can have very strong interactions with the brain’s natural or biological endocannabinoid system and can also modulate the effects of cannabinoids on the brain. If there is a dietary deficiency of Omega-3 fatty acids, the brain’s natural cannabinoid system is not going to work with optimal efficiency, Dr. Laviolette explained.

“By contrast, if you can supplement with Omega-3 fatty acids you see certain improvements in the brain’s cannabinoid system, so that immediately got us interested in how synergies between Omega-3 fatty acids and cannabinoids that are derived from marijuana might serve as potential, novel pharmaceutical and nutraceutical products for treating certain specific mental health disorders.”

The brain’s natural cannabinoid system is involved in a lot of different processes that relate to mental health, including mood regulation, one’s ability to learn and remember, and certain cognitive tasks.

“We know in certain mental health disorders like depression, addiction and schizophrenia, there’s a lot of disturbance in this cannabinoid system,” Dr. Laviolette continued. “So oftentimes people will sort of self-medicate with marijuana and perhaps expose themselves to some of the more negative aspects of it. One compound, in particular, called THC (tetrahydrocannabinol), can have negative effects, especially in younger adults, especially adolescents.”

Dr. Laviolette and his team have been comparing and contrasting THC versus other cannabinoids found in marijuana and seek to answer the question of: “What are some of the molecular pathways that they activate and how can we modulate different phytocannabinoids in their formulations and combine them with Omega-3’s to make them less likely to produce some of the negative side effects possible with marijuana exposure?”

“We’re looking at both the positive and negative effects, with the goal of really reducing or eliminating the negative effects and really sort of amplifying the positive chemicals that are found in marijuana in terms of treating some of these illnesses,” Dr. Laviolette said.

One of the biggest concerns of the medical community, and one reason a lot of doctors are not very willing to prescribe their patients cannabinoids in terms of treating mental health symptoms like PTSD, depression or even schizophrenia, relates to the potential negative side effects, he added.

“What we’re really trying to do is tease apart the positive and negative aspects of marijuana. We’ve been able to show CBD can actually be a promising treatment for a variety of mental health disorders like PTSD and schizophrenia,” Dr. Laviolette said. “It’s quite amazing because, when you think about it, it’s the same plant but these two different, competing chemicals are producing different effects in terms of mental health.”

Another major issue associated with using cannabinoids as a medical treatment is that people “aren’t really too keen on the idea of just smoking cannabinoids,” he said. “So, one of the major research directions we’re taking with Algae Dynamics is coming up with more effective non-smoked formats of medical marijuana, which includes oil-based formulations.”

Algae Dynamics’s focus on supporting research directed at the medical benefits of cannabis and hemp oils is providing a critical lifeline to scientists like Dr. Laviolette.

“The other aspect is that it’s very difficult to do this research because of all the different government regulations that you need to go through to, first; get ahold of the actual compounds, and second; get the actual license to perform these sorts of studies,” he said.

Canada is heading toward legalization of cannabis throughout the country in 2018, which could bode well for the research community, investors and companies like Algae Dynamics.

“People are excited. I think there’s a general feeling that cannabinoids are absolutely going to be an emerging biotechnology in the coming decades,” said Dr. Laviolette. “Companies like Algae Dynamics are actually taking this research seriously and are getting in on the ground floor of the development of effective cannabinoid products.”

While solid, quality research takes time, Dr. Laviolette said his team is now moving toward the clinical realm with the goal of collaborating with clinicians sometime within the next few months. Discovering the ideal ratios of THC and CBD and then combining those with a nutritional supplement such as Omega-3 fatty acids is expected to lead to the best formulations for an early stage clinical trial.

“I think there’s tremendous potential for development of pharmaceuticals and nutraceuticals based on that,” Dr. Laviolette says. “I’ve been doing this research for well over two decades now and what you consistently realize is that the existing drugs available for treating some of these symptoms have some really bad side effects. So, it’s not only the limited effectiveness of a lot of these drugs used to treat depression and anxiety, but the serious side effects that make a lot of people stop taking them. It’s essentially a barrier of sorts to long term treatment.”

Dr. Laviolette’s research is providing early, promising evidence that there are very few side effects associated with cannabidiol, or CBD, which is a non-psychoactive compound in marijuana.

“I think there’s tremendous potential to develop pharmacological treatments that are derived from natural products that are relatively pure. I think they’ll be a much more promising alternative than the more traditional medications that are out there right now,” he added.

Cannabis is a complex plant with well over 100 different phytochemicals, a fact that Dr. Laviolette describes as exciting but also one that means researchers are just barely beginning to “scratch the surface.”

For more information about Dr. Laviolette and his research with Algae Dynamics, visit the company’s website at www.AlgaeDynamics.com

Let us hear your thoughts: Algae Dynamics Corp. Message Board

• More than 5.3 million people in the U.S. have Alzheimer’s disease, which has no effective cure or substantial treatment
• India Globalization Capital’s IGC-ADI drug candidate targets proteins associated with the buildup of lesions in the brain
• The company acquired exclusive rights to a patent, based on University of South Florida studies supporting THC’s role in inhibiting Aβ plaque production

Alzheimer’s disease now affects over 5.3 million people in the United States, imposing an estimated economic cost of $236 billion. There has been no effective treatment to slow down or reverse its effects. That may be about to change, as India Globalization Capital, Inc. (NYSE MKT: IGC) launched a press release (http://dtn.fm/w01OQ) detailing its work on a drug candidate, IGC-ADI, that targets the buildup of lesions in the brain associated with Alzheimer’s. Given that the number of cases is expected to double over the next two decades, a lack of a cure or other mitigating therapy is concerning. However, the company expects to soon begin trials that may yield promising new treatments.

The unconventional nature of this drug candidate is that it is tetrahydrocannabinol (THC)-based. Low doses of THC have been found to inhibit amyloid beta peptide (Aβ plaque) production. This protein is believed to cause plaque to form in the cerebral cortex and hippocampus. Phosphorylated Tau proteins make up another type of lesion, called a neurofibrillary tangle, that is also linked to AD. The Aβ proteins normally cleared away by biological processes are unregulated in Alzheimer’s patients, and therefore build up into insoluble fibroles. The result is the formation of senile plaques and extracellular misfolded oligomers that are thought to be toxic to nerve cells in the brain.

Now the only publicly traded pharmaceutical cannabis stock that addresses the disease, IGC has developed a drug that inhibits protein production and protein aggregation and reduces the phosphorylation of protein, as explained in the recent Brand Awareness Distribution article, “Alzheimer’s Disease: Cannabis Formulation Shows Promise”. The drug candidate IGC-ADI is believed to also have the potential to restore mitochondria function and redirect the immune system. Studies on genetically engineered cell lines conducted at the University of South Florida (USF) have provided supportive evidence for the company to move forward. At THC concentrations of 25nM, Aβ40 production was cut by 30 percent over a six-hour period, and by 35 percent over 24 hours. When doses of 2.5 μM were introduced, amyloid beta peptide production was reduced by the same level at six hours, 40 percent over 24 hours, and 55 percent over 48 hours (compared to 40 percent at lower THC concentrations).

The patent “THC as a Potential Therapeutic Agent for Alzheimer’s Disease,” was filed based on the findings of the USF studies conducted by Dr. Chuanhai Cao, an Associate Professor of Pharmaceutical Sciences at USF’s College of Pharmacy and an IGC Senior Advisor. Expected to conduct human medical trials, IGC has already acquired exclusive rights to the patent filing, allowing it to use and advance the technology to find potential treatments for Alzheimer’s patients.

IGC-ADI is one of six patents involving cannabis-based combination therapy, providing investors with opportunities to help support potentially revolutionary treatments for Alzheimer’s, epilepsy, Parkinson’s disease, depression and post-traumatic stress disorder.

For more information, visit the company’s website at www.IGCInc.us

• ORHub is a pioneering cloud-based healthcare solution that can help medical providers eliminate inefficiencies, cut costs and improve quality of care
• ORHub has created a new category of healthcare IT vertical-specific software called surgical resource management (SRM)
• ORHub creates the largest source of intelligent surgical information in the world, opening up a vast pipeline of revenue opportunities
• ORHub is positioned to become the universal SRM platform for improving healthcare efficiency and cutting costs

“Value-based healthcare” is a buzz phrase these days, and surgical procedures are at the center of the issue, with hospitals spending, on average, between 48 and 50 percent of their revenues on surgery while outdated tracking systems cripplingly hold back progress, making it impossible for medical facilities to cut costs without sacrificing quality of care. One pioneering company, ORHub, Inc. (OTC: ORHB), has been working with Microsoft (http://dtn.fm/6zXs5) to break new ground and bring the United States healthcare system into the digital age—an evolution that is sorely needed in order to improve healthcare practices and lower costs in a country that is infamous for having the highest healthcare costs in the entire world.

The key is the ORHub solution, which has created the largest source of intelligent surgical information in the world and provides a suite of products that can better serve the needs of the healthcare industry, patients and the government. ORHub’s cloud-based software solution captures information at the point-of-care, filling a huge void in the surgical information infrastructure by transforming big data into intelligent data.

The ORHub solution replaces various antiquated legacy systems with a 360-degree solution that enables the tracking of healthcare costs from diagnosis to discharge, allowing all parties involved in surgical care to collaboratively organize, deliver, measure and reimburse via one intuitive, uniform program. This helps eliminate inefficiencies, duplication of services, and errors and omissions that currently result from siloed software processes and insufficient hand-offs across the care chain. The result will be substantially lowered healthcare costs and drastically improved patient outcomes.

The ORHub solution was born in a hospital surgery center, where forward-thinking surgeons and administrators realized they didn’t have the information they needed to reduce costs without negatively impacting quality of care. In the past, healthcare organizations have been blindly making decisions about how to improve their processes and redesign care without having a true understanding of the actual costs of care for a patient’s condition and how those costs relate to outcomes. Rather than working synergistically, clinicians have instead been battling over arbitrary cuts. ORHub’s cloud-based software platform is the solution to these inadequacies and inefficiencies.

Through ORHub’s software applications, hospitals and medical device vendors will be able to use any Web-enabled device to generate a detailed anatomical graphic depiction of what happens during surgery. The resulting schematic is then automatically translated into an intelligent electronic operative report that links every detail of a surgery to produce a dynamic new source of comparative data. Through ORHub’s revolutionary solution, hospitals, surgeons and vendors can now make decisions that are real-time and data-driven to improve both profitability and quality of care. Further, costs are resultantly reduced for both hospitals and vendors, accountability is improved, surgical implant registries are automated, real-time advanced analytics are created and compliance is bettered.

ORHub is disrupting archaic industry processes, making it possible for tasks that used to require teams of people working by hand to invest weeks or months to now be done directly at the point-of-care by just one person. For the very first time, surgical data can be utilized to create real-time evaluations, self-generate future statistical ratings, and provide predictive outcomes-of-care.

ORHub’s innovative cloud-based solution has created a new category of healthcare IT vertical-specific software called surgical resource management (SRM), which is a category that enables enhanced capabilities as well as access to valuable analytics. This SRM platform will create the largest source of intelligent surgical information the world has ever seen, simultaneously opening up a pipeline of revenue opportunities for ORHub. ORHub is positioned to become the universal SRM platform for improving efficiency and mitigating costs.

The ORHub story started in 2015, when company CTO Wesley Mitchell was contacted by the Microsoft for Startups Program to help a surgeon who wanted to develop a software program that could help analyze resource allocation for surgical procedures—a project that immediately intrigued Mitchell. Over a period of two months, he and his associates interviewed clinical and administrative professionals in the healthcare field and then applied for BizSpark Plus credit from the Microsoft for Startups Program to develop the ORHub solution. A pilot program was collaboratively developed by the ORHub team and Microsoft at the #5 orthopedic hospital in the nation. The solution was developed on the Microsoft Azure platform, which was already encrypted and built with HIPAA considerations in view. ORHub went from concept to production in under a year.

ORHub’s state-of-the-art, disruptive solution has the potential to drastically and lastingly impact the U.S. healthcare system, improving costs, patient outcomes, resource allocation and more. A brighter healthcare future is now within reach thanks to this pioneering technology.

For more information, visit the company’s website at www.ORhub.com

Let us hear your thoughts: ORHub, Inc. Message Board

• AppSwarm, Inc. reported $589,000 in revenue for 2016 and has continued to focus on growth in 2017
• The company has focused on four key revenue streams to boost the success of social game development, mobile apps, and e-commerce websites
• A proprietary screening process enables it to select app ideas with the most potential, based on their benefits for developers, entrepreneurs, and consumers

Earning $589,000 in revenue for 2016 hasn’t given AppSwarm, Inc. (OTC: SWRM) a reason to slow down. From in-house development to assets gained through mergers and acquisitions, the company has focused on a vigorous growth strategy centered on a proprietary business model. This is known internally as the “Swarm”. The publicly traded company has focused on engagement, retention, virality, and monetization to secure its revenue streams and sustain its position in a high-demand market, boost the value of its products, and continue a pattern of growth, all at the same time.

The four key revenue streams driving the company’s progress include the incubation of apps, using completion of concept and development, market analysis, sales/marketing, and financial management services. AppSwarm is also highly engaged in social game development. It has developed highly relevant concepts internally, although it has also been successful in purchasing and redeveloping existing games and applications. Focusing on specialty niches has boosted revenue as well, especially casino and role-playing movie-themed applications. Several projects have involved partnerships leveraging technology and market expertise, allowing the company to apply each product to the specific market in an appropriate way.

Continual growth has been facilitated by AppSwarm’s unique approach to product development. Its proprietary selective screening process involves a detailed review of each app idea’s benefits. The decision-making process is considered beneficial for developers and entrepreneurs, but this isn’t the only strategy employed. Mergers and acquisitions aren’t unusual in software development, but the company’s expertise and support in business management/development, capital, and other areas contributes to its repeated success in the M&A circuit.

E-commerce, health, and education represent just a few of the sectors the company’s M&A strategy has focused on. Its e-commerce development has concentrated on the mobile device market and the anticipated increase in online sales driven by purchasing activity of potentially 270 million people by 2020, according to Forrester Research Inc. AppSwarm’s e-commerce development has delved into the world of virtual reality. It has also contributed to the success of websites such as Urban Bamboo Designs, an online retailer of low carbon footprint products, and Authlinks, an authority links resource serving bloggers and website owners.

AppSwarm has also built its revenue by tapping into the $99.6 billion global games market. From soccer to the battlefield to fun family game apps, the company has taken gamers to diverse realms. An optical character recognition-enabled application for scanning PDF documents universally works on all iPhones and iPads. The company’s focus on entertainment, productivity, and web development has enabled it to reach into a large market base, provide useful services for end users, and grow its revenue and position with investors/developers from all walks of life.

For more information, visit the company’s website at www.App-Swarm.com

Let us hear your thoughts: AppSwarm, Inc. Message Board

• SinglePoint has completed its third acquisition of 2017
• Company’s revenue has grown 378-fold since first quarter 2017
• Delivery application in development will directly compete with Leafly and WeedMaps
• Company well-positioned to continue acquisition strategy and further increase revenue

Marking its third acquisition of 2017, SinglePoint, Inc. (OTC: SING) announced on September 6 that it has acquired profitable cannabis distribution company Dr. FeelGood. According to the agreement terms, SinglePoint will acquire 51 percent of the company in a combination of cash and stock, allowing SinglePoint to recognize all revenue.

This acquisition adds yet another revenue stream for SinglePoint, further affirming the company’s strategy of revenue by acquisition. The acquisition further provides SinglePoint with new team members who have been active within the cannabis industry for many years.

Based in Phoenix, Arizona, Dr. FeelGood is a leading medical marijuana distribution company that has expansion plans to add a proprietary delivery and ordering technology application. Dr. FeelGood’s founders have established a development plan to create a proprietary mobile application that will both enhance the experience for users and streamline the company’s operations. The app is scheduled to be released within 90 days. Once the app is completed, both companies will be able to license the technology to other distribution companies throughout the United States.

The two companies are also collaborating on a delivery platform, and SinglePoint will leverage its location-based delivery application and add other features, including a directory and ordering system that will compete directly with Leafly and WeedMaps. Dr. FeelGood was already pursuing plans to build the app; with SinglePoint’s progress, the company will be able to utilize the app much earlier than anticipated and begin providing it to interested entities.

Dr. FeelGood offers a broad array of products that are distributed through both B2B and B2C. Current owners Scott Riley and Jeff Clevenger will continue overseeing the company’s day-to-day operations, with plans in view to expand the business and license the Dr. FeelGood brand in other states.

Other SinglePoint acquisitions that have taken place in 2017 include California-based companies DIGS Hydro and Convectium. With these acquisitions, SinglePoint’s revenue has increased 378-fold in comparison with 2017’s first quarter, ideally positioning the company like never before. SinglePoint is well-capitalized to continue its acquisition strategy and further increase revenues.

For more information, visit the company’s website at www.SinglePoint.com

Let us hear your thoughts: SinglePoint, Inc. Message Board

• Company engages Launch Haus LLC, a digital agency, to grow its direct-to-consumer e-commerce business through a new marketing campaign
• Consilium Global Research (http://dtn.fm/P49cZ) projects a CAGR of nearly 100% for CIIX through FY2020, with revenues reaching $14.8 million
• CIIX has goal of becoming the largest Chinese publicly traded company in the legalized cannabidiol (CBD) market, with a target audience of the global Chinese-speaking community

ChineseInvestors.com, Inc.’s (OTCQB: CIIX) goal of growing its global sales of hemp-based cannabidiol (CBD) products will be aided by its engagement of Launch Haus LLC, a Scottsdale, Arizona-based holding company specializing in digital direct-to-consumer marketing and product branding.

CIIX has a goal of becoming the primary Chinese medical cannabis publicly traded company. It is focused on the research and development and distribution of legalized CBD to the global Chinese-speaking community. It has an online store in the free trade zone of Shanghai, China, and plans to open a brick-and-mortar store in its home market of San Gabriel, California. Sales of CBD are legal in China, while marijuana is not.

In a recent update, WallStreetResearch.org (http://dtn.fm/a4DV4) noted, “Launch Haus has been engaged to develop a customized cutting-edge direct response marketing campaign that will focus on personalized, customer-centric marketing and sales force automation; develop a compensation plan that incentivizes both rapid growth through recruitment of new, entry-level consumers and top-tier distributors; introduce CIIX to its stable of industry-leading suppliers for global payment systems and logistics and its network of distributor recruitment and legal governance and compliance professionals.”

The report added that the principals of Launch Haus have a proven track record of building sales organizations and developing go-to-market planning and customer experience consulting. CIIX, it notes, believes it is on track to announce an official launch date of its direct selling platform in the coming fiscal year.

Consilium Global Research projects that CIIX will achieve sales of $14.8 million by FY2020, outpacing the growth of the CBD market with a compound annual growth rate (CAGR) of nearly 100% in that time period.

Let us hear your thoughts: ChineseInvestors.com, Inc. Message Board

• Crystal Equity Research, encouraged by new joint venture strategy, forecasts rising revenue for Moxian (http://dtn.fm/Q8Fva)
• Key to market growth is UnionPay’s payment module in Moxian+ app
• MOXC now targets larger $2-4 million businesses for Moxian+ Merchant app sales

Moxian, Inc. (NASDAQ: MOXC) has changed its business strategy to grow more quickly within China, targeting the nation’s top four markets while also beginning to utilize a joint venture strategy in order to penetrate these markets more efficiently with the aid of entrenched businesses. MOXC’s marketing and sales team members are now acting as sales managers, working with independent agents to secure higher volume.

MOXC, an integrated platform operator focused on processing digital payments, is converting its unpaid platforms to paid platforms. Key to its new strategy is MOXC’s relationship with China’s dominant payment processor, UnionPay. A UnionPay processing module on the Moxian+ platform is critical in allowing MOXC to attract new joint venture partners in China and neighboring Asian markets. Now, the Moxian+ Merchant platform offers digital processing modules for UnionPay, Alipay, and WeChatPay.

“We anticipate revising our revenue estimates upward when Moxian confirms the formalization of the joint venture with Shewn International,” the Crystal Equity Research report said. It now projects MOXC revenues at $2.3 million by FY2018.

Crystal Equity Research sees the joint ventures as strengthening and making more efficient Moxian’s plans to penetrate the markets of Beijing, Shanghai, Shenzhen, and Guangzhou. “We view it as an important catalyst for valuation,” the report said. It added that such joint ventures could raise investor confidence in the company and result in higher valuation of shares.

The joint venture with Shewn International Group of Shanghai gives MOXC a new revenue stream from a percentage earned on all its processing of payments from Shewn. Further, Crystal Equity Research notes that MOXC is burning less cash with the new joint venture strategy. It noted that the company used only $1.3 million in cash during the quarter ended June 2017 versus the $5.4 million the company spent in the prior quarter. The reduction was attributed to reduced selling, general and administrative (SG&A) costs with the new tactics.

Shewn International, in addition to its fine wine sales in wine clubs, also plans to open as many as 500,000 new vending machines across China to sell its fine wines. Affluent residents of luxury apartment complexes, Shewn believes, will react positively to the convenience of buying its upscale wines, offered at the correct temperature and humidity, from these machines.

For more information, visit the company’s website at www.Moxian.com